CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Elanco Animal Health (NYSE: ELAN) Investors to Inquire About a Securities Fraud Class Action by December 6, 2024

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities between November 7, 2023, and June 26, 2024, due to significant stock price decline following FDA approval updates [1][6]. Company Overview - Elanco Animal Health develops products for pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [3]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [4]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q3 2024 with a launch in Q4 2024 [4]. - On June 27, 2024, Elanco indicated that Zenrelia would likely include a boxed safety warning, which could slow product adoption by approximately 25%, and revised its approval expectations to Q3 2024 for Zenrelia and Q4 2024 for Credelio Quattro [5]. Stock Price Impact - Following the FDA approval news, Elanco's stock price fell by $3.69 per share, or 20$14.28 per share on June 27, 2024 [6].